A long-acting protein medicine that activates GLP-1 receptors.
Chinese adults with overweight or obesity without diabetes
Study contextApproved for T2D in China; phase 2b/3 obesity program ongoing.
Status sourceStatus & indications10.58% reported weight loss · 3.61% loss with placebo · 18 weeks
ENLIGHT phase 2b · Phase 2b · sponsor · 20 mg once weekly · Other / incompletely specified
Evidence & limitationsMostly mild/moderate GI events; no premature AE discontinuations or drug-related serious events.
Safety contextA next milestone is not summarized for this therapy.
Milestone detailsStudy results apply to their own population, dose and analysis. They do not establish a ranking between therapies.
Each result belongs to its own study population, dose and analysis. Open a result for its chart, comparator, safety findings and limitations.
10.58% reported weight loss · 3.61% loss with placebo · 18 weeks
20 mg once weekly
Chinese adults with overweight or obesity without diabetes
Not specified in public report Approved for T2D in China; phase 2b/3 obesity program ongoing.
Mostly mild/moderate GI events; no premature AE discontinuations or drug-related serious events.
Limitations: Conference abstract; exact estimand not reported; distinct molecule from efpeglenatide.
Status in this atlas: Approved for T2D in China; phase 2b/3 obesity program ongoing. Status source
A long-acting protein medicine that activates GLP-1 receptors.
What do these hormones do? GLP-1
Guangzhou Innogen Pharmaceutical Group · Originator, developer and commercial supplier; also developing obesity and MASH indications.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
A long-acting protein medicine that activates GLP-1 receptors.
Shown: Protein drug / fusion construct
An exact-drug structure was not verified in this review. The named PubChem lookup did not return a compound record; no related hormone or analogue is substituted.
Efsubaglutide alfaEfsubaglutide alfa · compound history across indications
Selected milestones only. Earlier studies may be missing; the first listed date should not be interpreted as the start of development.
NMPA approved efsubaglutide alfa injection for adults with type 2 diabetes.
SourceInnogen's company history records approval in Macau for adult type 2 diabetes.
SourceThe phase 2b conference abstract reported results in adults with overweight or obesity; obesity remains distinct from the approved diabetes indication.
SourceSelected sources checked Sep 13, 2026. This is not an exhaustive history.